PartnershipUpdated on 30 April 2026
Areas of Interest for international collaboration
About
Our goal is to develop treatments and expand the indications for our active immunosuppressive ingredient, GJK-012, to target Sjögren’s syndrome dry eye disease (via eye drops), atopic dermatitis (AD), inflammatory bowel disease (IBD), and multiple sclerosis (MS). To achieve this, we aim to to collaborate with pharmaceutical companies and researchers specializing in each of these respective fields.
Organisation
Similar opportunities
Partnership
Areas of Interest for international collaboration
Young Ho Kim
Chief Executive Officer at AT-31 BIO Inc.
Daegu, South Korea
Partnership
Do Youn Chun
Chief Technical Officer at AT-31 BIO Inc.
Daegu, South Korea
Project cooperation
Portfolio Company Collaboration: 20/20 OptimEyes Technologies
- Research
- Execution
- Technical
- Biotech, Pharma and Cosmetics
Renaud Jacquemart
CEO at Omnium Global
Burlington, Canada